Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
E De Clercq, C Desgranges, P Herdewijn, I S Sim, A S Jones, M J McLean, R T Walker
Index: J. Med. Chem. 29 , 213, (1986)
Full Text: HTML
Abstract
(E)-5-(2-Bromovinyl)uracil (BVU) and (E)-5-(2-bromovinyl)uridine (BVRU) were synthesized starting from 5-formyluracil via (E)-5-(2-carboxyvinyl)uracil or starting from 5-iodouridine via (E)-5-(2-carbomethoxyvinyl)uridine and (E)-5-(2-carboxyvinyl)uridine, respectively. Depending on the choice of the cell system, BVU and BVRU exhibited a marked activity against herpes simplex virus type 1 (HSV-1) in vitro. Although BVU and BVRU were less potent than the reference compound (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), their antiviral activity spectrum was remarkably similar to that of BVDU. The latter findings suggest that BVU and BVRU are metabolically converted to BVDU or a phosphorylated product thereof. In vivo, BVU protected mice against a lethal disseminated HSV-1 infection.
Related Compounds
Related Articles:
2012-07-01
[Biochem. J. 445(1) , 113-23, (2012)]
Synthesis of nucleoside-based antiviral drugs in ionic liquids.
2008-10-15
[Bioorg. Med. Chem. Lett. 18(20) , 5640-2, (2008)]
2010-01-01
[Nucleosides Nucleotides Nucleic Acids 29(1) , 1-13, (2010)]
Interaction between capecitabine and brivudin in a patient with breast cancer.
2010-01-01
[Nat. Rev. Clin. Oncol. 7(1) , 55-8, (2010)]
2011-08-01
[Med. Microbiol. Immunol. 200(3) , 193-202, (2011)]